NURIX THERAPEUTICS INC (NRIX) Stock News

USA - NASDAQ:NRIX - US67080M1036 - Common Stock

9.84 USD

-0.19 (-1.89%)

Last: 10/17/2025, 8:00:01 PM

9.64 USD

-0.2 (-2.03%)

After Hours: 10/17/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

NRIX Latest News, Press Relases and Analysis

All

Press Releases

10 days ago - By: Chartmill

News Image

NURIX THERAPEUTICS INC (NASDAQ:NRIX) Misses Q3 2025 Estimates, Shares Drop

a day ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

9 days ago - By: Benzinga

Breaking Down Nurix Therapeutics: 5 Analysts Share Their Views

9 days ago - By: Stocktwits

News Image

Nurix Stock Falls After-Hours After Wider Q3 Loss; Oppenheimer Sees FDA Support For Bexo, Retail Buys The Dip

10 days ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

a month ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

2 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Participate in Upcoming Investor Conferences

3 months ago - By: Benzinga

6 Analysts Assess Nurix Therapeutics: What You Need To Know

3 months ago - By: Stocktwits - Mentions: GILD

Nurix Therapeutics Posts Better-Than-Expected Q2 Results; Revenue Soars on Sanofi and Gilead Payments

3 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

4 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström

4 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

5 months ago - By: Yahoo Finance - Mentions: SNY BPMC VZ DHI ...

Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout

5 months ago - By: Nurix Therapeutics, Inc.

Sanofi Exercises License Extension Option to Nurix’s STAT6 Program

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

5 months ago - By: Yahoo Finance - Mentions: DHI CMG

Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

6 months ago - By: Nurix Therapeutics, Inc.

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update